TAG:
clinical trials
LabCorp And Quest Report 3rd Quarter Financial Performance
CEO Summary: In third quarter earnings reports, both national lab companies posted modest gains in specimen volume, revenue, and net profit. More telling is the relative quiet in the current market for lab testing services. With no obvious opportunities to fuel double-digit rates of growt…
Rapid Genome Sequencing Predicted by Mid-2009
CEO SUMMARY: In the same way that the Human Genome Project was disrupted by the entry of C. Craig Venter and Perkin-Elmer in what was then a 15-year, $3 billion project, now Complete Genetics of Mountain View, California, is disrupting the race to the $1,000 human genome sequence. Develop…
Low Vitamin D Linked To Greater Risk of Death
CEO SUMMARY: A new report in the Archives of Internal Medicine is likely to further spur demand for vitamin D testing. Already, labs are dealing with a dramatic increase in testing for vitamin D deficiency, with test volumes more than doubling in the past 12 months. This new research is c…
Is Digital Path Imaging Ready for Prime Time?
CEO SUMMARY: Digital pathology imaging systems are finding uses in all phases of drug discovery (discovery, pre-clinical, clinical trials), as well as education, research, and clinical. One hurdle to widespread adoption of fully digitized, whole-slide pathology imaging systems is FDA clea…
July 7, 2008 “Intelligence: Late Breaking Lab News”
GI Pathology, PLLC, of Memphis, Tennessee, announced that it has contracted to be a national gastrointestinal (GI) pathology laboratory provider with CIGNA HealthCare of Hartford, Connecticut. It also has a five year, national provider contract with UnitedHea…
GE, UPMC Create Company for Digital Path Imaging
CEO SUMMARY: It’s a new joint venture with the potential to transform surgical pathology. General Electric Healthcare has extensive experience at supporting physicians’ work flow with digitized imaging systems, plus ample experience with molecular bio-markers. The University of Pittsb…
Bostwick Labs Prepares For Public Stock Offering
CEO SUMMARY: In recent years, annual revenue at Bostwick Laboratories has skyrocketed, reaching $102.8 mil- lion in 2007. Now the company, known for its national uropathology expertise, has filed documents in preparation for an initial public stock offering (IPO). Bostwick Laboratories is…
Growing NeoGenomics Offers FISH Test TC/PC
CEO SUMMARY: This specialty lab testing company now has laboratories in Fort Meyers, Florida; Nashville, Tennessee; and Irvine, California. It recently beefed up its executive ranks and is adding to its menu of genetic and molecular assays. In December, 2006, NeoGenomics …
Joint Venture Launches Molecular Pathology Lab
CEO SUMMARY: As genomic medicine advances, researchers into various diseases quickly recognize the need to incorporate molecular pathologists onto their teams. In Grand Rapids, Michigan, a large integrated health system and a private research institute have come together to jointly fund a…
Genomic Health, TriPath Imaging, Bio-Reference Labs, Canadian Patient Registry
PREDICTIVE TESTING FOR RECURRENT BREAST CANCER LABORATORY TESTS DESIGNED to predict the recurrence of breast cancer are picking up momentum. First to market was Genomic Health Inc.’s Oncotype DX™ breast cancer test. Now TriPath Imaging, Inc. is reporting…
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.